Regimen Reference Order – CUTA – trametinib + daBRAFenib (Adjuvant)

ARIA: CUTA - [trametinib + daBRAFenib (ADJ)]

Planned Course: **Until disease progression or unacceptable toxicity up to a maximum of one year (1 cycle = 30 days)**

Indication for Use: **Melanoma BRAF mutation positive, Resected, Adjuvant**

Proceed with treatment if:

- ***ANC equal to or greater than 1.2 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L***
- ***ALT less than 3 times the upper limit of normal***
- ***Total bilirubin less than 2 times the upper limit of normal***
- ***Creatinine clearance equal to or greater than 30 mL/minute***
  - **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CUTA – trametinib + daBRAFenib (Adjuvant)

Drug	Dose	CCMB Administration Guideline
trametinib	2 mg	Orally once daily on an empty stomach To be taken at the same time as morning dose of daBRAFenib Swallow whole **(Self-administered at home)**
daBRAFenib	150 mg	Orally twice daily on an empty stomach Swallow whole **(Self-administered at home)**

trametinib (MEKINIST®) available dosage strengths: 0.5 mg and 2 mg tablets
Classification: Cytotoxic, Hazardous

daBRAFenib (TAFINLAR®) available dosage strengths: 50 mg and 75 mg capsules
Classification: Cytotoxic, Hazardous

REQUIRED MONITORING

Cardiac monitoring

- EKG and Left Ventricular Ejection Fraction (LVEF) at baseline and every 3 to 6 months during treatment at the physician's discretion

All Cycles

- CBC, serum creatinine, electrolytes, liver enzymes, total bilirubin and blood glucose as per Physician Orders
- Clinical skin toxicity and nail assessment
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- Serious non-infectious fever can occur. Patients should be instructed to contact their cancer team if they develop any fever greater than **39.5 degrees Celsius** or any fever with chills
- trametinib and daBRAFenib should be taken on an empty stomach with a glass of water at least one hour before or two hours after a meal
- Evening dose of daBRAFenib should be taken approximately 12 hours after morning dose
- This regimen has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- trametinib is stored in the refrigerator. The desiccant should not be removed
- daBRAFenib is stored at room temperature
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on trametinib and daBRAFenib

ADDITIONAL INFORMATION

- Reinforce applicable safe handling precautions of medications, blood and body fluids while on trametinib and daBRAFenib
- Serious febrile drug reactions may occur and may be accompanied by severe rigors or chills, dehydration, hypotension or renal failure (in the absence of infection). Interruption of therapy and symptom management may be required to manage pyrexia
- This regimen can prolong QT interval and PR interval
- trametinib has been associated with interstitial lung disease and pneumonitis
- trametinib and daBRAFenib have been associated with ocular toxicity
- trametinib and daBRAFenib will be dispensed by CCMB Pharmacy